South Easton, MA – Pressure BioSciences, Inc. (“PBI” or the “Company”) today reiterated its optimistic revenue and operational outlook for the third and fourth quarters of 2011, as discussed during the Company’s recent Q2 2011 conference call. During the call, the Company stated its belief that:

Total revenue for the second half of FY 2011 would be significantly greater than total revenue for the first half of FY 2011

PCT Products revenue for Q3 2011 would exceed PCT Products revenue for any quarter over the past year

PCT Sample Preparation System installations for Q3 2011 would exceed the number of PCT

Sample Preparation System installations for the first or second quarter of 2011

PBI was making significant progress towards signing at least one major, worldwide, PCT

Products distribution agreement in 2011

PBI remained on track to release its pressure-enhanced formalin-fixed, paraffin-embedded (FFPE) protein extraction service in late 2012

PBI remained optimistic that it will raise the capital necessary to support its continued operations and growth plan during the second half of 2011 and beyond

Mr. Richard T. Schumacher, President and CEO of PBI, said: “The first half of 2011 was a very difficult and disappointing period for all of us at PBI. However, the hard work and dedication of our employees during this time resulted in the expansion of market awareness for our PCT Platform, the development of several important new applications for the PCT Sample Preparation System, and the release of two novel and exciting instruments: the Barocycler HUB440 and the Shredder SG3. We believe that momentum has begun to swing in our favor and that the second half of 2011 will be significantly better in revenue, instrument installations, and in the development of strategic partnerships, as compared to the first half of the year.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a NASDAQ Capital Market listed company focused on the development and sale of instrumentation and consumables based on a novel, enabling technology platform called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 24 issued patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced bio-molecule extraction and enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.